Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

550
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
550
Drug Therapy01:28

Drug Therapy

315
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
315
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

940
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
940
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

943
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
943
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

872
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
872
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

964
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
964

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Processing speed and working memory span: their differential role in superficial and deep memory processes in schizophrenia.

Journal of the International Neuropsychological Society : JINS·2011
Same author

Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study.

Journal of psychopharmacology (Oxford, England)·2010
Same author

Serial and semantic encoding of lists of words in schizophrenia patients with visual hallucinations.

Psychiatry research·2010
Same author

Production of atypical category exemplars in patients with schizophrenia.

Journal of the International Neuropsychological Society : JINS·2010
Same author

Depression, avolition, and attention disorders in patients with schizophrenia: associations with verbal memory efficiency.

The Journal of neuropsychiatry and clinical neurosciences·2009
Same author

Working memory span and motor and cognitive speed in schizophrenia.

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology·2009
Same journal

An overview of the safety and efficacy of sphenopalatine ganglion stimulation for the treatment of chronic cluster headache.

Expert review of neurotherapeutics·2026
Same journal

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same journal

Remote deep brain stimulation programming in childhood dystonia: opportunities, challenges, and future directions.

Expert review of neurotherapeutics·2026
Same journal

The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis.

Expert review of neurotherapeutics·2026
Same journal

Corticosteroids in withdrawal therapy following medication-overuse headache: a systematic review.

Expert review of neurotherapeutics·2026
Same journal

Clinical efficacy of lacosamide in neuropathic pain: a systematic review of randomized controlled trials.

Expert review of neurotherapeutics·2026
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K

New targets for antipsychotics.

Hugh M Jones1, Lyn S Pilowsky

  • 1Section of Neurochemical Imaging, Institute of Psychiatry, Denmark Hill, London, SE5 8AF, UK.

Expert Review of Neurotherapeutics
|October 9, 2009
PubMed
Summary
This summary is machine-generated.

Novel antipsychotic drug development focuses on targeting dopamine, glutamate, and serotonin receptors. These strategies aim to improve efficacy for resistant schizophrenia while minimizing side effects, especially for early-onset patients.

More Related Videos

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

12.0K
Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

75.8K

Related Experiment Videos

Last Updated: Feb 17, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K
Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

12.0K
Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

75.8K

Area of Science:

  • Neuroscience and Pharmacology
  • Psychiatry and Mental Health

Background:

  • Atypical antipsychotics offer improved side effect profiles over older neuroleptics.
  • Clozapine demonstrates superior efficacy in treatment-resistant schizophrenia.
  • Understanding neurochemical profiles guides novel antipsychotic drug development.

Purpose of the Study:

  • To explore novel therapeutic strategies for schizophrenia based on receptor pharmacology.
  • To identify potential targets for improving cognitive function and treating resistant symptoms.
  • To contextualize research within early-onset schizophrenia care and pharmacogenomics.

Main Methods:

  • Review of neurochemical profiles of atypical antipsychotic agents.
  • Analysis of dopaminergic (D1, D2, D3), glutamatergic (NMDA), and serotonergic (5-HT) receptor targets.
  • Consideration of pharmacogenomic advancements.

Main Results:

  • Two distinct strategies for novel antipsychotic development are suggested: targeted dopaminergic agents and multi-receptor modulators.
  • D3 receptor antagonists and combined D2/autoreceptor partial agonists are potential avenues.
  • D1 receptor modulation may enhance cognitive function in schizophrenia.
  • Glutamate and various serotonin receptor targets show promise for resistant symptoms and side effect reduction.

Conclusions:

  • Targeting specific dopaminergic, glutamatergic, and serotonergic pathways offers promising strategies for developing more effective and safer antipsychotic medications.
  • Future antipsychotic drug development should consider multi-target approaches and personalized medicine through pharmacogenomics.
  • Addressing the needs of first-episode schizophrenia patients is crucial in advancing treatment.